Althaus Karina, Hoepner Gero, Zieger Barbara, Prüller Florian, Pavlova Anna, Boeckelmann Doris, Birschmann Ingvild, Müller Jens, Rühl Heiko, Sachs Ulrich, Kehrel Beate, Streif Werner, Bugert Peter, Zaninetti Carlo, Cooper Nina, Schulze Harald, Knöfler Ralf, Bakchoul Tamam, Jurk Kerstin
Medical Faculty of Tübingen, Institute for Clinical and Experimental Transfusion Medicine, Tübingen, Germany.
Center for Clinical Transfusion Medicine, University Hospital of Tübingen, Tübingen, Germany.
Hamostaseologie. 2025 Jan 27. doi: 10.1055/a-2404-0216.
Congenital platelet disorders are rare and targeted treatment is usually not possible. Inherited platelet function disorders (iPFDs) can affect surface receptors and multiple platelet responses such as defects of platelet granules, signal transduction, and procoagulant activity. If iPFDs are also associated with a reduced platelet count (thrombocytopenia), it is not uncommon to be misdiagnosed as immune thrombocytopenia. Because the bleeding tendency of the different platelet disorders is variable, a correct diagnosis of the platelet defect based on phenotyping, function analysis, and genotyping is essential, especially in the perioperative setting. In the case of a platelet receptor deficiency, such as Bernard-Soulier syndrome or Glanzmann thrombasthenia, not only the bleeding tendency but also the risk of isoimmunization after platelet transfusions or pregnancy has to be considered. Platelet granule disorders are commonly associated with either intrinsically quantitative or qualitative granule defects due to impaired granulopoiesis, or granule release defects, which can also affect additional signaling pathways. Functional platelet defects require expertise in the clinical bleeding tendency in terms of the disorder when using antiplatelet agents or other medications that affect platelet function. Platelet defects associated with hematological-oncological diseases require comprehensive information about the patient including the clinical implication of the genetic testing. This review focuses on genetics, clinical presentation, and laboratory platelet function analysis of iPFDs with or without reduced platelet number. As platelet defects affecting the cytoskeleton usually show thrombocytopenia, but less impaired or normal platelet functional responses, they are not specifically addressed.
先天性血小板疾病较为罕见,通常无法进行针对性治疗。遗传性血小板功能障碍(iPFDs)可影响表面受体以及多种血小板反应,如血小板颗粒缺陷、信号转导和促凝活性。如果iPFDs还伴有血小板计数减少(血小板减少症),被误诊为免疫性血小板减少症的情况并不少见。由于不同血小板疾病的出血倾向各不相同,基于表型分析、功能分析和基因分型对血小板缺陷进行正确诊断至关重要,尤其是在围手术期。对于血小板受体缺乏症,如伯纳德 - 索利尔综合征或血小板无力症,不仅要考虑出血倾向,还必须考虑血小板输注或妊娠后发生同种免疫的风险。血小板颗粒疾病通常与由于粒细胞生成受损导致的内在定量或定性颗粒缺陷有关,或者与颗粒释放缺陷有关,这也可能影响其他信号通路。功能性血小板缺陷在使用抗血小板药物或其他影响血小板功能的药物时,需要专业知识来判断疾病的临床出血倾向。与血液肿瘤疾病相关的血小板缺陷需要了解患者的全面信息,包括基因检测的临床意义。本综述重点关注伴有或不伴有血小板数量减少的iPFDs的遗传学、临床表现和实验室血小板功能分析。由于影响细胞骨架的血小板缺陷通常表现为血小板减少症,但血小板功能反应受损较轻或正常,因此本文不做具体讨论。